Sarepta Therapeutics: Keep on Climbing

Sarepta Therapeutics (SRPT) surged 39% yesterday after the FDA’s surprise decision to consider an early application for its cerebral palsy drug. And today its shares keep climbing. AP Wedbush’s Christopher Marai and team outline the bull’s case: We believe that the FDA’s guidance paves the way for accelerated approval (AA) of eteplirsen. The FDA guidance appears [...]